Extract
Evidence-based guidelines recommend the combination of macrolide–ethambutol–rifamycin as first-line treatment for Mycobacterium avium complex pulmonary disease (MAC-PD) [1]. Whether this regimen results in improved survival is unknown.
Abstract
No significant difference in mortality among patients treated with different antibiotic regimens for Mycobacterium avium pulmonary disease https://bit.ly/3abXjDJ
Acknowledgement
We thank IMS Brogan Inc. for use of their Drug Information Database.
Footnotes
Conflict of interest: S.K. Brode reports grants from Insmed Pharmaceuticals and Canadian Institutes of Health Research (CIHR), personal fees for educational activities from Boehringer Ingelheim and AstraZeneca, outside the submitted work.
Conflict of interest: H. Chung has nothing to disclose.
Conflict of interest: M.A. Campitelli has nothing to disclose.
Conflict of interest: J.C. Kwong has nothing to disclose.
Conflict of interest: R. Sutradhar has nothing to disclose.
Conflict of interest: A. Marchand-Austin has nothing to disclose.
Conflict of interest: K.L. Winthrop reports grants and personal fees from Insmed, personal fees from Johnson & Johnson, Paratek, Red Hill Biopharma and Horizon, outside the submitted work.
Conflict of interest: F.B. Jamieson has nothing to disclose.
Conflict of interest: T.K. Marras reports grants and personal fees for consultancy from Insmed, personal fees for educational activities from AstraZeneca, France Foundation and Novartis, personal fees for consultancy from Horizon and RedHill, outside the submitted work.
Support statement: This study was supported by ICES and Public Health Ontario (PHO), which are funded by annual grants from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by ICES, PHO, or the Ontario MOHLTC is intended or should be inferred. Parts of this material are based on data and/or information compiled and provided by the Canadian Institute of Health Information (CIHI). However, the analyses, conclusions, opinions and statements expressed herein are those of the authors, and not necessarily those of CIHI.
- Received October 7, 2019.
- Accepted April 8, 2020.
- Copyright ©ERS 2020